Warning: The NCBI web site requires JavaScript to function. more...
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L.
Breast Cancer Res. 2008;10(1):R10. Epub 2008 Feb 1.
Related citations
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.
Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG.
Cancer Immunol Immunother. 2009 Aug;58(8):1185-94. Epub 2008 Dec 2.
Isolation and identification of cancer stem-like cells from murine melanoma cell lines.
Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L, Zhao F, Jiang C, Hu W, Hu K, Gu N.
Cell Mol Immunol. 2007 Dec;4(6):467-72.
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.
Breast Cancer Res. 2008;10(3):R53. Epub 2008 Jun 17.
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.
Fillmore CM, Kuperwasser C.
Breast Cancer Res. 2008;10(2):R25. Epub 2008 Mar 26.
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.
J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. Epub 2010 Oct 8.
Cancer stem cell heterogeneity in hereditary breast cancer.
Wicha MS.
Breast Cancer Res. 2008;10(2):105. Epub 2008 Apr 16.
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
Clin Cancer Res. 2009 Jun 15;15(12):4234-41. Epub 2009 Jun 9.
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.
Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, Tarkkanen M, Tanner M, Hakkarainen T, Kanerva A, Desmond RA, Pesonen S, Hemminki A.
Mol Ther. 2007 Dec;15(12):2088-93. Epub 2007 Sep 11.
Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells.
Vassilopoulos A, Wang RH, Petrovas C, Ambrozak D, Koup R, Deng CX.
Int J Biol Sci. 2008 May 4;4(3):133-42.
CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R.
Cancer Biol Ther. 2010 Dec 1;10(11):1182-90. Epub 2010 Dec 1.
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.
Breast Cancer Res Treat. 2010 Jul;122(2):315-24. Epub 2009 Oct 1.
Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H, Srour EF, Badve S.
Curr Stem Cell Res Ther. 2009 Jan;4(1):50-60. Review.
A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, Xu J, Cao QH, Zhu HQ, Wang F.
Chin Med J (Engl). 2008 Oct 20;121(20):1980-6.
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.
PLoS One. 2011;6(6):e20636. Epub 2011 Jun 13.
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.
Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.
Breast Cancer Res. 2006;8(5):R59.
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers.
Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ, Lee WH.
PLoS One. 2009 Dec 21;4(12):e8377.
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.
Cancer Res. 2009 Oct 15;69(20):8058-66. Epub 2009 Oct 13.
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J.
J Clin Pathol. 2011 Nov;64(11):937-46. Epub 2011 Jun 16.
Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.
Rappa G, Lorico A.
Exp Cell Res. 2010 May 15;316(9):1576-86. Epub 2010 Jan 11.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on